Enochian Biosciences Inc.（纳斯达克股票代码：ENOB）2月份空头利率上涨5.6％

Enochian Biosciences Inc. (NASDAQ:ENOB – Get Rating) saw a significant growth in short interest in February. As of February 28th, there was short interest totalling 1,500,000 shares, a growth of 5.6% from the February 13th total of 1,420,000 shares. Based on an average trading volume of 55,200 shares, the days-to-cover ratio is presently 27.2 days. Approximately 9.9% of the company's shares are short sold.

Hedge Funds Weigh In On Enochian Biosciences

A number of large investors have recently made changes to their positions in the company. Rafferty Asset Management LLC lifted its holdings in Enochian Biosciences by 52.4% during the 2nd quarter. Rafferty Asset Management LLC now owns 25,258 shares of the company's stock worth $49,000 after buying an additional 8,688 shares during the period. Cubist Systematic Strategies LLC increased its holdings in Enochian Biosciences by 101.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,990 shares of the company's stock worth $50,000 after acquiring an additional 13,090 shares during the last quarter. Millennium Management LLC increased its holdings in Enochian Biosciences by 59.2% in the 4th quarter. Millennium Management LLC now owns 52,814 shares of the company's stock worth $54,000 after acquiring an additional 19,631 shares during the last quarter. Rhumbline Advisers purchased a new position in Enochian Biosciences during the 2nd quarter valued at about $55,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Enochian Biosciences during the 3rd quarter valued at about $67,000. Institutional investors own 7.16% of the company's stock.

Enochian Biosciences Stock Performance

Shares of ENOB stock remained flat at $1.02 on Friday. The stock had a trading volume of 27,845 shares, compared to its average volume of 47,571. The business has a fifty day moving average of $1.12 and a 200-day moving average of $1.55. Enochian Biosciences has a 52 week low of $0.90 and a 52 week high of $9.16. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.48 and a quick ratio of 0.48. The stock has a market cap of $56.82 million, a price-to-earnings ratio of -1.24 and a beta of 1.22.

Enochian Biosciences Company Profile

(Get Rating)

Enochian Biosciences, Inc is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21.

Read More

• Get a free copy of the StockNews.com research report on Enochian Biosciences (ENOB)
• 3 Stocks For A Defensive Tech Portfolio
• Milk the Dividends on These 3 Cash Cows
• Europe Raises Interest Rates, Should the Fed Follow?
• PacWest Bancorp May Escape a Credit Downgrade After this Happens
• Dollar General Offers Great Prices, but the Stock isn't a Value

Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.